ChIP assays revealed that recruitment of HP1α to the TNFα and the examined HERV promoters was significantly reduced in the MS patients compared to their genetically related healthy controls, while recruitment to a control promoter (RPLP0) was unchanged (Figure 6C). Here, RPLP0 is linked to myeloid sarcoma.